期刊
NEUROLOGY
卷 96, 期 19, 页码 E2438-E2450出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0000000000011896
关键词
-
资金
- project HERCULES consortium
- Duchenne UK
- Pfizer
- PTC Therapeutics
- Roche
- Summit Therapeutics plc
- Sarepta Therapeutics Inc
- Wave Lifesciences USA Inc
- Solid Biosciences
- Catabasis Pharmaceuticals
- Santhera Therapeutics
This study describes the development of a new DMD-QoL quality of life self-report measure in three stages, generating draft items from qualitative interviews, refining a reduced item set through cognitive debriefing, and producing a final 14-item questionnaire with good psychometric properties for boys and men with DMD.
Objective Based on concerns about existing patient-reported outcome measures (PROMs) for assessing quality of life (QoL) in Duchenne muscular dystrophy (DMD), we describe the mixed methods development of a new QoL PROM for use in boys and men with DMD: the DMD-QoL. Methods The DMD-QoL was developed in 3 stages. First, draft items were generated from 18 semistructured qualitative interviews with boys and men with DMD, analyzed using framework analysis. Second, cognitive debriefing interviews with patients (n = 10), clinicians (n = 8), and patients' parents (n = 10) were undertaken, and a reduced item set was selected and refined. Third, psychometric data on the draft items from a cross-sectional online survey (n = 102) and stakeholder input from patients and patients' parents were used to produce the final questionnaire. Patient and public involvement and engagement was embedded throughout the process. Results From an initial draft of 47 items, a revised set of 27 items was produced at stage 2, and this set was further refined at stage 3 to generate the DMD-QoL, a 14-item QoL PROM. The DMD-QoL is designed for use from 7 years of age by proxy report and from 10 years of age by self-report or proxy report. The final measure showed good psychometric properties. Conclusion The DMD-QoL is a new 14-item QoL PROM for boys and men with DMD, with demonstrable content and face validity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据